Previous studies from our group and others have also detected high levels of phosphorylated Akt in CTCL patients [35, 42–44], highlighting the importance of using AKT/mTOR signaling pathway-related targets in CTCL treatment [44, 45]. Here, AKT1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.